Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors

Citations Over TimeTop 13% of 2023 papers

Abstract

Immune checkpoint inhibitor (ICI) therapy is insensitive for Colorectal cancer (CRC) patients with microsatellite stable (MSS). Genomic data of three CRC cohort, n = 35), and the Cancer Genome Atlas (TCGA CRC cohort, n = 377), were analyzed. A cohort treated with ICIs from Memorial Sloan Kettering Cancer Center (MSKCC CRC cohort, n = 110) and two cases from the local hospital were characterized the impact of the HRR mutation on prognosis of CRC. Homologous recombination repair (HRR) gene mutations were more common in CN and HL cohorts (27.85%; 48.57%) than in TCGA CRC cohort (15.92%), especially in the MSS populations, the frequencies of HRR mutation were higher in CN and HL cohort (27.45%, 51.72%) than in TCGA cohort (6.85%). HRR mutations were associated with high tumor mutational burden (TMB-H). Although HRR mutation uncorrelated with an improved overall survival in the MSKCC CRC cohort (p = 0.97), HRR mutated patients had a significantly improved OS compared to the HRR wildtype population particularly in MSS subgroups (p = 0.0407) under ICI treatment. It probably contributed by a higher neoantigen and increased CD4+ T cell infiltration which found in the TCGA MSS HRR mutated CRC cohort. The similar phenomenon on cases was observed that MSS metastatic CRC patient with HRR mutation seemed more sensitive to ICI after multi-line chemotherapy in clinical practice than HRR wildtype. This finding suggests the feasibility of HRR mutation as an immunotherapy response predictor in MSS CRC, which highlights a potential therapeutic approach for these patients.

Related Papers

• → TC22, a Novel Colorectal Cancer Biomarker Remains Continuously Suppressed Upon Repeated Mesalamine Exposure to Colorectal Cancer Cells(2011)
• δ-catenin Expression Correlates with Cell Proliferation in Colorectal Cancer(2013)
• Expression of PTTG and its significance in colorectal cancer(2008)
• → Expression of Galecitn-9 in colorectal cancer and its clinical significance(2023)
• → SLC25A24, a potential and novel biomarker for diagnosing colorectal cancer(2023)